DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer.

达拉斯——（商业新闻短讯）——星光治疗公司（Starlight Therapeutics）——一家Lantern Pharma（纳斯达克股票代码：LTRN）的子公司，专注于中枢神经系统和脑癌治疗的临床开发，但治疗选择有限或无效——今天宣布，医学博士马克·张伯伦（MarcChamberlain）加入星光公司，担任其首席医疗官。

Dr. Chamberlain will oversee Starlight’s clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas, brain metastases in adults, and atypical teratoid rhabdoid tumors (ATRT), and diffuse pontine glioma (DIPG) in children. In his role, Dr. Chamberlain will apply his significant medical, clinical, and pharmaceutical development expertise to advance Starlight’s AI-enabled and accelerated drug development portfolio..

张伯伦博士将监督Starlight的临床操作，目前包括胶质母细胞瘤和其他高级别胶质瘤，成人脑转移瘤，非典型畸胎样横纹肌样瘤（ATRT）和儿童弥漫性脑桥胶质瘤（DIPG）的计划临床试验。张伯伦博士将运用其重要的医学、临床和药物开发专业知识，推进星光公司的人工智能和加速药物开发组合。。

Dr. Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric neurology and neuro-oncology. His experience before joining Starlight has included serving as the co-director of the neuro-oncology programs at 4 NCI designated cancer centers— Moores Cancer Center at UC San Diego, Norris Cancer Center at USC, Moffit Cancer Center at the University of South Florida, and Fred Hutchinson Cancer Center at the University of Washington.

张伯伦博士是一位领先的医学肿瘤学家，在治疗开发，临床实践和学术研究方面具有广泛而独特的背景，重点是成人和儿科神经病学和神经肿瘤学。他在加入Starlight之前的经验包括在4个NCI指定的癌症中心担任神经肿瘤学项目的联合主任-加州大学圣地亚哥分校的摩尔癌症中心，南佛罗里达大学的诺里斯癌症中心，南佛罗里达大学的莫菲特癌症中心，以及华盛顿大学的弗雷德·哈钦森癌症中心。

He has also served as medical director for Cascadian Therapeutics, Seattle Genetics, SystImmune, Angiochem, and Pionyr Immunotherapeutics. Dr. Chamberlain has published more than 300 neurology-focused papers in peer-reviewed journals..

他还曾担任Cascadian Therapeutics，Seattle Genetics，SystImmune，Angiochem和Pionyr Immunotherapeutics的医学总监。张伯伦博士在同行评审期刊上发表了300多篇以神经病学为重点的论文。。

“Starlight Therapeutics and Lantern Pharma are poised to transform oncology with AI-enabled drug development aimed at providing advanced precision therapeutics for cancers in areas of severely unmet need, such as multiple types of pediatric and adult brain cancers, for which there is currently no cure,” said Panna Sharma, CEO and President of Lantern Pharma.

Lantern Pharma首席执行官兼总裁潘娜·夏尔玛（Panna Sharma）表示：“星光疗法和Lantern Pharma准备通过人工智能药物开发来改变肿瘤学，旨在为严重未满足需求的癌症领域提供先进的精确治疗方法，如多种类型的儿科和成人脑癌，目前尚无治愈方法。”。

“Dr. Chamberlain’s insight and expertise in neuro-oncology and therapeutic development will be invaluable to the further development of treatments already in the pipeline, and the discovery and development of new future treatments that are so desperately needed by cancer patients, especially in neuro-oncology.”.

“张伯伦博士在神经肿瘤学和治疗发展方面的见识和专业知识对于已经在进行的治疗的进一步发展，以及癌症患者迫切需要的新的未来治疗方法的发现和开发，尤其是在神经肿瘤学方面，将是无价的。”。

Dr. Chamberlain earned his medical degree at the Columbia University College of Physicians and Surgeons, followed by pediatric and neurology residencies at the University of California, Los Angeles, and a neuro-oncology fellowship at the University of California, San Francisco.

张伯伦博士在哥伦比亚大学内科医生和外科医生学院获得医学学位，随后在洛杉矶加利福尼亚大学获得儿科和神经病学住院医师学位，并在旧金山加利福尼亚大学获得神经肿瘤学奖学金。

“Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001” for CNS indications), to target tumors in the brain. We are now preparing for two recurrent glioblastoma studies as part of a larger planned expansion study to assess STAR-001 in subjects who have failed standard-of-care temozolomide and involved field radiotherapy.

“Starlight与Lantern Pharma合作，准备推进其新型中枢神经系统（CNS）渗透剂全合成酰基氟乙烯LP-184（CNS适应症称为“STAR-001”），以靶向大脑肿瘤。我们现在正在准备进行两项复发性胶质母细胞瘤研究，作为一项更大规模的计划扩展研究的一部分，以评估替莫唑胺治疗标准失败且涉及野外放疗的受试者的STAR-001。

The development of STAR-001 for use in brain tumors has utilized Lantern’s proprietary RADR® platform of in silico modeling as well as extensive preclinical experimentation in multiple in-vitro and in-vivo models,” said Dr. Chamberlain. “I’m looking forward to working alongside the talented researchers and experts at Lantern and its collaborators at Starlight who have already done so much to advance these treatments.

用于脑肿瘤的STAR-001的开发利用了Lantern专有的RADR®计算机模拟平台，以及多种体外和体内模型的广泛临床前实验，”张伯伦博士说。“我期待着与Lantern的天才研究人员和专家以及Starlight的合作者一起工作，他们已经为推进这些治疗做了很多工作。

I look forward to working together with our collaborators and clinicians to bring these and many more innovative neuro-oncology treatments to the patients who need them.”.

我期待着与我们的合作者和临床医生合作，为需要的患者带来这些和更多创新的神经肿瘤学治疗。”。

Formed in Q1 of 2023, Starlight Therapeutics is leveraging RADR®— Lantern Pharma’s proprietary artificial intelligence and machine learning platform focused on transforming the cost, pace and timeline of oncology drug discovery and development— to research, develop and clinically advance therapeutics for CNS and brain cancers..

Starlight Therapeutics成立于2023年第1季度，目前正在利用RADR®（Lantern Pharma专有的人工智能和机器学习平台），专注于改变肿瘤药物发现和开发的成本、速度和时间表，以研究、开发和临床推进中枢神经系统和脑癌的治疗方法。。

About Lantern Pharma

关于Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) RADR® platform leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development.

Lantern Pharma（纳斯达克股票代码：LTRN）是一家AI公司，它改变了肿瘤药物发现和开发的成本、速度和时间表。我们专有的人工智能和机器学习（ML）RADR®平台利用了600多亿个以肿瘤学为中心的数据点和200多种先进的ML算法库，帮助解决肿瘤学药物开发中数十亿美元的现实问题。

By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program..

通过利用人工智能的力量以及世界级科学顾问和合作者的投入，我们加速了我们不断增长的治疗渠道的发展，包括11种癌症适应症和抗体-药物偶联物（ADC）计划。平均而言，我们新开发的药物计划在2-3年内从最初的人工智能见解发展为首次人体临床试验，每个计划约为100-200万美元。。

Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options.

我们的潜在客户开发计划包括2期临床计划和多个1期临床试验。我们还成立了一家全资子公司Starlight Therapeutics Inc.，专门专注于我们有前途的中枢神经系统和脑癌治疗方法的临床实施，其中许多治疗方法没有有效的治疗选择。

Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world..

据估计，我们由人工智能驱动的创新产品候选渠道的年市场潜力合计超过150亿美元，并有可能为全球数十万癌症患者提供改变生活的疗法。。

Forward-looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of STAR-001 and our other product candidates; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of STAR-001 and our other drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and biomarker data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明。这些前瞻性报表除其他事项外，还包括与以下事项有关的报表：未来事件或我们未来的财务业绩；STAR-001和我们其他候选产品的潜在优势；我们的RADR®平台在识别可能对候选药物产生反应的候选药物和患者人群方面的潜在优势；我们的战略计划是推进STAR-001和其他候选药物和抗体-药物偶联物（ADC）开发计划的开发；关于我们候选药物和ADC开发计划的开发时间的估计；关于临床试验时间和患者登记的期望和估计；我们的内部药物发现计划的研究和开发工作以及利用我们的RADR®平台来简化药物开发过程；我们打算利用人工智能，机器学习和生物标志物数据来简化和改变肿瘤药物发现和开发的速度，风险和成本，并确定可能对候选药物产生反应的患者人群；关于患者人群，潜在市场和潜在市场规模的估计；我们对候选药物的销售估计以及我们发现和开发候选药物的计划，并通过自己或与他人合作推进这些候选药物来最大限度地发挥其商业潜力。

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expe.

任何不属于历史事实陈述的陈述（包括但不限于使用“预期”、“相信”、“沉思”、“可能”、“估计”、“体验”等词语的陈述）。